Immunotherapy

Immunotherapy has gained clinical importance in recent years, primarily as a result of advancement in cancer treatment and modulation of inflammatory diseases. Immunotherapy means modulating the immune response either through enhancement or repression of the patient’s immune system. A wide range of new drugs that modulate the immune system are under development, and they all share the advantage of specific action on a single target. This increases therapeutic safety and reduces side effects comparing to traditional treatment options.

This course aims to evaluate modern immunotherapy and the future perspective of immune modulation. We will focus on the two axes of immunotherapy – enhancement of immune activity as is often used to treat cancer, and inhibition of immune activation as is done in treatment of inflammatory disease. The course will introduce different diseases with potential for immunotherapy. This includes different common types of cancer and inflammatory disease, but also rare immunodeficiencies, with well-described genetic origins. The mechanisms of action of the immunotherapies will be discussed in details including antibody-based therapies, T-cell-directed therapy, and small molecule inhibitors of specific signalling pathways.

Course leader

Martin Kristian Thomsen

Target group

Master's Level

Fee info

EUR 675: EU/EEA citizens
EUR 1520: NON EU/EEA citizens

Scholarships

No scholarships available

Register for this course
on course website